Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $43 | $61 | $39 | $16 | $17 |
| Gross Profit | $31 | $48 | $31 | $8 | $6 |
| Operating Income | -$15 | $13 | -$83 | -$94 | -$37 |
| Net Income | -$19 | $7 | -$84 | -$93 | -$38 |
Over the five-year period, VERU Inc.'s revenue and profitability metrics have experienced considerable volatility. In 2020, the company generated approximately 42.6 million USD in revenue with a gross profit of about 30.8 million USD, though it posted a net loss of roughly 19.0 million USD. A significant turnaround occurred in 2021 when revenue increased by nearly 44% to 61.3 million USD, gross profit improved to 47.9 million USD, and the company moved into profitability with an operating income of 13.0 million USD and net income of 7.4 million USD. However, this positive momentum was not sustained. In 2022, revenue dropped about 36% to 39.4 million USD with gross profit declining similarly, and both operating income and net income plunged into deeper losses at around -83.2 million USD and -83.8 million USD, respectively. The downturn continued in 2023 with revenue decreasing sharply to 16.3 million USD—a drop of over 58% from the previous year—accompanied by a corresponding decline in gross profit to 7.6 million USD. Although 2024 saw a marginal increase in revenue to 16.9 million USD, both operating income and net income remained significantly negative, though the losses appear to have moderated slightly compared to 2023. The dramatic swings, particularly the year-over-year shifts observed between 2021 and 2022 and again in 2023, suggest the impact of operational challenges or shifts in market conditions that are common in the biotech industry. Overall, while the 2021 turnaround offered a glimpse of potential, the subsequent steep declines raise concerns about the company’s financial sustainability and its ability to stabilize revenue streams and manage operating costs effectively in a volatile industry environment.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.